POLYPHARMACY IN AGEING POPULATIONS: NEUROLOGICAL RISKS, HEALTHCARE DETERMINANTS AND DIGITAL INTERVENTIONS IN EUROPE

Vollständiger Abstract

Worum geht es in dieser Arbeit?

As Europe’s population ages, managing polypharmacy has evolved from an individual clinical concern into a major public health priority [3, 4]. Broadly driven by multi-organ chronic diseases and uncoordinated specialist care, the accumulation of multiple drug prescriptions generates heavy clinical and economic costs [5, 6]. This narrative review maps the neurological risks linked to polypharmacy and evaluates the structural healthcare factors that shape prescribing habits across European nations [1, 12]. Gathering data published between 2010 and 2024, we synthesized evidence regarding regional prevalence, cumulative anticholinergic burden, and system-level weaknesses [4, 14]. Current statistics reveal that 40–50% of older Europeans aged ≥ 65 years face polypharmacy, though rates differ widely between countries [4, 24]. The central nervous system bears a disproportionate share of drug-induced harm; common outcomes include accelerated cognitive decline, acute delirium, motor instabilities, and the worsening of pre-existing psychiatric or epileptic conditions [13, 14, 19]. Much of this damage stems directly from an unmonitored anticholinergic burden, which tracks closely with elevated dementia rates and mortality [15, 16]. At the institutional level, fragmented communication between physicians, poor access to comprehensive geriatric assessments, and the absence of routine medication reviews act as primary drivers of unsafe prescribing [2, 26]. Mitigating these risks requires integrating targeted organizational shifts—such as mandatory deprescribing protocols and clinical pharmacist oversight—with digital infrastructure, including artificial intelligence platforms and clinical decision-support software [7, 31, 33, 34].